EGFP saRNA (Cap-1; 5mCTP)

EGFP self-amplifying RNA (saRNA) (Cap-1; 5mCTP) encodes enhanced GFP (EGFP), a variant of A. victoria GFP containing chromophore mutations that increase the sensitivity of the protein and displays excitation/emission maxima of 489/511 nm, respectively.¹ It is capped with the Cap-1 structure to increase translation efficiency and modified with 5-methylcytidine-5'-triphosphate (5mCTP) to reduce the host cell immune response. EGFP saRNA (Cap-1; 5mCTP) is based on the self-replicating Venezuelan equine encephalitis virus (VEEV), which results in stable expression of EGFP. It can be used as a control for the delivery and translation efficiency of RNA. Encapsulation of EGFP saRNA in lipid nanoparticles (LNPs) has been used for saRNA delivery and expression of EGFP in vitro.²

WARNING This product is not for human or veterinary use.

1. Zhang, G., Gurtu, V., and Kain, S.R. An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells. Biochem. Biophys. Res. Commun. 227(3), 707-711 (1996).

2. Sun, Z., Liu, Y., Zhang, H., et al. A novel alphavirus-based saRNA platform for enhanced vaccination efficacy and organ-specific targeting. Vaccine 72, 128055 (2026).